Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials
News Dec 09, 2010
Selcia Limited, an independent provider of Carbon-14 (C-14) radiolabelling services, announces that its radiochemistry facility has been granted a Good Manufacturing Practice (GMP) certificate for the preparation and C-14 labelling of Active Pharmaceutical Ingredients (APIs) for clinical trials following a successful inspection by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
Commenting on the award, Selcia’s Managing Director, Dr Hans Fliri said: “With market demand increasing for GMP radiolabelling, we are pleased that we can now offer pharmaceutical and biotech companies cost effective radiolabelling services to support both the pre-clinical and clinical development of their new medicines. Selcia’s extended capability of now being able to produce GMP radiolabelled API material will shorten the timeframe for our clients to commence key Phase 1 clinical trials”.
Director of Radiochemistry Dr Gill Little said: “Our radiochemistry team continues to focus on delivering the best possible tailored service. Together with our GLP analytical laboratory we can supply the high quality products that our customers expect”.
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE